Comparing 3 drug combos for newly diagnosed AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether a new combination (DEC3-VEN) works better than two other standard treatments for people with newly diagnosed acute myeloid leukemia (AML). The goal is to find the best initial therapy to help achieve remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age between 16 and 64 years old.
- Must have a new diagnosis of AML (not a subtype called APL or certain favorable genetic types).
- You haven't had any prior AML treatment except maybe hydroxyurea or low-dose cytarabine to lower blood counts.
- Your overall health is good enough for intensive chemotherapy (a performance status of 0-2).
- Your liver and kidney function tests must be within certain safe limits.
- You are not pregnant or nursing, and you agree to use effective birth control during the study and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, venetoclax and a hypomethylating agent, as the first treatment for adults newly diagnosed with acute myeloid leukemia (AML). The goal is to see if this combination works well and is safe.
This trial tests a combination of three chemotherapy drugs (venetoclax, azacitidine, and cytarabine) for people newly diagnosed with acute myeloid leukemia who have never received AML treatment before. The goal is to see if this combination can help patients go into remission and live longer.
This trial is testing a combination of venetoclax and azacitidine in people with acute myeloid leukemia (AML) who have a high percentage of blast cells (at least 20%) in their bone marrow or blood. It aims to see if this treatment approach can improve outcomes for patients regardless of previous treatments or transplant history.
This trial tests a combination of three drugs—daunorubicin, cytarabine, and venetoclax—for people with newly diagnosed AML who are strong enough to receive intensive chemotherapy. The goal is to see if adding venetoclax helps improve treatment outcomes.
This trial compares four different combinations of targeted therapy and chemotherapy for people with newly diagnosed AML who cannot have standard intensive chemo. The goal is to see which combination works best safely.
This trial compares a new combination of drugs (venetoclax, azacitidine, and liposomal mitoxantrone) against a standard chemotherapy regimen (idarubicin and cytarabine) for people with newly diagnosed acute myeloid leukemia (AML). It tests whether the new combination works better and is safe.
Hear when a new AML (Acute Myeloid Leukemia) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.